Cutaneous infiltration by T-cell prolymphocytic leukemia in two adult patients
Main Article Content
Keywords
Lymphoproliferative Disorders, Leukemic Infiltration, T-cell, Prolymphocytic, Leukemia
Abstract
Background: T-cell prolymphocytic leukemia (T-PLL) is a T-cell lymphoproliferative disorder that frequently involves the skin. The objective was to describe two cases of T-PLL with cutaneous involvement and to present a review of the literature concerning the clinical characteristics, differential diagnosis and treatment of these patients.
Case reports: 1) 79 year-old man, with a previous diagnosis of T-PLL based on a laboratory incidental finding. He had been treated with alemtuzumab, but it had to be interrupted due to recurrent infections. After interrupting the treatment, the patient developed a symmetrical rash on his extremities. The skin biopsy demonstrated TPLL infiltration. 2) 28 year-old man that presented with asthenia and lymphocytosis. He also showed a purpuric rash on his trunk and facial erythema. Histopathology of the skin and bone marrow confirmed the diagnosis of T-PLL with cutaneous involvement.
Conclusions: T-cell prolymphocytic leukemia accounts for 2% of mature leukemias in adults. Skin involvement is reported in 20-50% of the patients. The characteristic features are facial involvement, purpuric lesions and symmetry of the rash, although there are atypical manifestations as well. Differential diagnosis includes other T-cell lymphoproliferative disorders with hematologic and skin involvement, such as Sézary syndrome. Patients with T-PLL may show cutaneous infiltration at the moment of debut or relapse of the disease. The skin is an accessible organ for taking samples to study and diagnose these patients.
References
1. Matutes E, Brain BJ, Wotherspoon A. Lymphoid malignancies. An atlas of investigation and diagnosis. Oxford:Clinical Publishing;2007. 101-18, 123-8.
2. Sud A, Dearden C. T-cell prolymphocytic leukemia. Hematol Oncol Clin North Am. 2017;31:273-83.
3. Hsi AC, Robirds DH, Luo J, Kreisel FH, Frater JL, Nguyen TT. T-cell prolymphocytic leukemia frequently shows cutaneous involvement and is associated with gains of MYC, loss of ATM, and TCL1A rearrangement. Am J Surg Pathol. 2014;38:1468-83.
4. Magro CM, Morrison CD, Heerema N, Porcu P, Sroa N, Deng AC. T-cell prolymphocytic leukemia:an aggressive T cell malignancy with frequent cutaneous tropism. J Am Acad Dermatol. 2006;55:467-77.
5. López-Pestaña A. Infiltración cutánea por una leucemia prolinfocítica T simulando una púrpura diseminada. Actas Dermosifiliogr. 1999;90:443-6.
6. Kakkar N, Calton N, John MJ. T cell prolymphocytic leukemia (T-PLL):cutaneous involvement in an uncommon leukemia. Indian J Hematol Blood Transfus. 2018;34(3):573-4. doi:10.1007/s12288-018-0932-2
7. Pulido N, Medina G, Palomino N, Peralta F. Manifestaciones cutáneas de las leucemias. Rev Med Inst Mex Seguro Soc. 2015;53(Supl 1):S30-5.
8. Khullar G, Singh S, Agrawal S, Sachdeva MUS, Saikia UN. Linear nonpalpable purpura in a young male:a unique presentation of leukemia cutis in T-cell prolymphocytic leukemia. Int J Dermatol. 2017;56(3):e65-7.
9. Cruz-Manzano M, Ramírez-García L, Sánchez-Pont JE, Velázquez-Mañana AI, Sánchez JL. Rosacea-like leukemia cutis:a case report. Am J Dermatopathol. 2016;38:119-21.
10. Siu SY, Jiang Q, Alpdogan O, Gochoco A, Gong J, Lee JB, et al. Bullous leukemia cutis in a patient with T-cell prolymphocytic leukemia. J Am Acad Dermatol. 2016;2:287-9.
11. Peña C, Valladares X, Soto C, Encina A, Marinov N, Undurraga MS, et al. Cerebriform variant type of T cell prolymphocytic leukemia:report of one case. Rev Med Chil. 2016;144(1):124-8.
12. Ashturkar AV, Pathak GS, More YE, Bhandare A. T-cell prolymphocytic leukemia with cutaneous involvement as the presenting feature. Indian J Dermatol. 2012;57:157-8.
13. Gru A, Schaffer A. Hematopathology of the skin:a clinical and pathologic approach. Philadelphia:Lippincott Williams &Wilkins;2016.
14. Sia PI, Figueira E, Kuss B, Craig J, Selva D. T-cell large granular lymphocyte leukemia in the lower eyelid. Ophthal Plast Reconstr Surg. 2016;32:e12.
15. Matutes E. Adult T-cell leukaemia/lymphoma. J Clin Pathol. 2007;60:1373-7.
16. Khanlari M, Ramos JC, Sanchez SP, Cho-Vega JH, Amador A, Campuzano-Zuluaga G, et al. Adult T-cell leukemia/lymphoma can be indistinguishable from other more common T-cell lymphomas. The University of Miami experience with a large cohort of cases. Modern Pathology. 2018;31(7):1046-63.
17. Dearden C. Management of prolymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2015;2015:361-7.
18. Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, et al. Alemtuzumab therapy in T-cell prolymphocytic leukemia:comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood. 2011;118(22):5799-802.
19. Campath Distribution Program (US HCPs Only) Provider Portal. Disponible en https://www.campathproviderportal.com. Actualizado Diciembre 2019;consultado 4 Abril 2020.
20. Los-Arcos I, Aguilar-Company J, Ruiz-Camps I. Risk of infection associated with new therapies for lymphoproliferative syndromes. Med Clin (Barc). 2020;154(3):1017. doi:10.1016/j.medcli.2019.07.026
21. Österborg A, FoàR, Bezares RF, Dearden C, Dyer MJS, Geisler C, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia. 2009;23(11):1980-8.
22. O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008;111(4):1816-9.
23. Krishnan B, Else M, Tjonnfjord GE, Cazin B, Carney D, Carter J, et al. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone:a multicentre retrospective study:Correspondence. Br J Haematol. 2010;149(6):907-10.
24. Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, et al. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood. 2019;134(14):1132-43.
25. Babu MCS, Anand A, Lakshmaiah KC, Babu KG, Lokanatha D, Jacob LA, et al. T-cell prolymphocytic leukemia:an experience from a tertiary cancer centre in South India. Int J Hematol Oncol Stem Cell Res. 2018;12(2):132-5.
26. Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, et al. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol. 2017;28(7):1554-9.
27. Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink AM, et al. Sequential therapy of fludarabine, mitoxantrone and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. Cancer. 2013;119(12):2258-67.
28. Herbaux C, Genet P, Bouabdallah K, Pignon J-M, Debarri H, Guidez S, et al. Bendamustine is effective in T-cell prolymphocytic leukaemia. Br J Haematol. 2015;168(6):916-9.
29. López C, Bergmann AK, Paul U, Murga Penas EM, Nagel I, Betts MJ, et al. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia. Br J Haematol. 2016;173(2):265-73.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.